Moxalactam Disodium

Research use only, not for human use.

Moxalactam sodium salt is an antibiotic compound more effective against Escherichia coli and Pseudomonas aeruginosathan cephalosporins.

Moxalactam sodium salt is an antibiotic compound more effective against Escherichia coli and Pseudomonas aeruginosathan cephalosporins.(In Vitro):Moxalactam (Latamoxef) inhibits 90% of strains of Escherichia coli, Klebsiella species, Proteus species, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae and Salmonella species, including strains which are resistant to Cephalothin (HY-B1275A) and Gentamicin (HY-A0276A) at concentrations of less than 1 μg/mL.Moxalactam exhibits moderate activity against P. aeruginosa and is usually active against other species of Pseudomonas, Acinetobacter species are usually resistant to Moxalactam.Moxalactam has marked stability in vitro against a variety of β-lactamases, including that produced by B. fragilis, inhibits production of β-lactamases and does not induce class I β-lactamase.(In Vivo):Moxalactam (Latamoxef) (0-7.4 mg/mouse; s.c.; once) is effective against bacterial infections in mice.

Moxalactam (Latamoxef) inhibits 90% of strains of Escherichia coli, Klebsiella species, Proteus species, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae and Salmonella species, including strains which are resistant to Cephalothin (HY-B1275A) and Gentamicin (HY-A0276A) at concentrations of less than 1 μg/mL.Moxalactam exhibits moderate activity against P. aeruginosa and is usually active against other species of Pseudomonas, Acinetobacter species are usually resistant to Moxalactam.Moxalactam has marked stability in vitro against a variety of β-lactamases, including that produced by B. fragilis, inhibits production of β-lactamases and does not induce class I β-lactamase.

Moxalactam (Latamoxef) (0-7.4 mg/mouse; s.c.; once) is effective against bacterial infections in mice. Animal Model:Four-week-old male strain ICR mice, weighing 18-20 g, bacterial infection model Dosage:0-7.4 mg/mouse Administration:Subcutaneous injection, once Result:Showed protective activity with ED50s less than 7.4 mg/mouse against gram-positive and gram-negative bacteria infected mice.

Moxalactam Disodium | Latamoxef, Sodium Salt

Endocrinology/Hormones

AChR

Antibacterial

Infection

——

64953-12-4

564.44

C20H18N6Na2O9S

>98% (HPLC)

DMSO : ≥ 38 mg/mL; 67.32 mM

[H][C@]12OCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)[C@H](C(=O)O[Na])C1=CC=C(O)C=C1)OC)C(=O)O[Na]

sodium (6R,7R)-7-(2-carboxylato-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

(-20℃)

With Ice Pack

≥ 2 years